These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 32077861)
1. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. Ho ACH; Wong SN; Leung LCK; Chan WKY; Chong PCY; Tse NKC; Yeung RHM; Kong SY; Lee KP Hong Kong Med J; 2020 Feb; 26(1):56-65. PubMed ID: 32077861 [TBL] [Abstract][Full Text] [Related]
2. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Windschall D; Müller T; Becker I; Horneff G Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081 [TBL] [Abstract][Full Text] [Related]
4. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD; Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303 [TBL] [Abstract][Full Text] [Related]
5. Choice and switch of biologic drugs in juvenile idiopathic arthritis. Şener S; Başaran Ö; Batu ED; Cüceoğlu MK; Balık Z; Aliyev E; Bayındır Y; Bilginer Y; Özen S Turk J Pediatr; 2023; 65(6):980-989. PubMed ID: 38204313 [TBL] [Abstract][Full Text] [Related]
6. Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis. Lahiri M; Teng GG; Cheung PP; Suresh E; Chia FL; Lui NL; Koh DR; Koh WH; Leong KP; Lim AYN; Ng SC; Thumboo J; Lau TC; Leong KH Int J Rheum Dis; 2017 Oct; 20(10):1527-1540. PubMed ID: 26353916 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. Davies R; Gaynor D; Hyrich KL; Pain CE Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689 [TBL] [Abstract][Full Text] [Related]
8. Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. Scott C; Chan M; Slamang W; Okong'o L; Petty R; Laxer RM; Katsicas MM; Fredrick F; Chipeta J; Faller G; Pileggi G; Saad-Magalhaes C; Wouters C; Foster HE; Kubchandani R; Ruperto N; Russo R Clin Rheumatol; 2019 Feb; 38(2):563-575. PubMed ID: 30267356 [TBL] [Abstract][Full Text] [Related]
9. The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: a systematic review. Ungar WJ; Costa V; Burnett HF; Feldman BM; Laxer RM Semin Arthritis Rheum; 2013 Jun; 42(6):597-618. PubMed ID: 23337074 [TBL] [Abstract][Full Text] [Related]
10. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S; Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312 [TBL] [Abstract][Full Text] [Related]
11. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133 [TBL] [Abstract][Full Text] [Related]
12. Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis. Buckley L; Ware E; Kreher G; Wiater L; Mehta J; Burnham JM J Rheumatol; 2020 Feb; 47(2):273-281. PubMed ID: 31308202 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort. Glerup M; Rypdal V; Arnstad ED; Ekelund M; Peltoniemi S; Aalto K; Rygg M; Toftedal P; Nielsen S; Fasth A; Berntson L; Nordal E; Herlin T; Arthritis Care Res (Hoboken); 2020 Apr; 72(4):507-516. PubMed ID: 30762291 [TBL] [Abstract][Full Text] [Related]
16. Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single-center experience. Bouayed K; Hamraoui D; Mikou N; Sakhi A; Hilmi W Pan Afr Med J; 2022; 41():135. PubMed ID: 35519160 [TBL] [Abstract][Full Text] [Related]
17. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A Arthritis Rheumatol; 2017 Aug; 69(8):1538-1551. PubMed ID: 28620948 [TBL] [Abstract][Full Text] [Related]
18. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N; Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296 [TBL] [Abstract][Full Text] [Related]
19. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations. Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515 [TBL] [Abstract][Full Text] [Related]
20. [Current therapy of polyarticular forms of juvenile idiopathic arthritis]. Hospach A; Rühlmann JM; Weller-Heinemann F Z Rheumatol; 2016 Apr; 75(3):284-91. PubMed ID: 27001055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]